These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Editor's Choice - efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Kakkos SK, Kirkilesis GI, Tsolakis IA. Eur J Vasc Endovasc Surg; 2014 Nov; 48(5):565-75. PubMed ID: 24951377 [Abstract] [Full Text] [Related]
11. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Imberti D, Pomero F, Benedetti R, Fenoglio L. Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399 [Abstract] [Full Text] [Related]
12. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials. Loffredo L, Violi F, Perri L. Int J Cardiol; 2016 Jun 01; 212():255-8. PubMed ID: 27057930 [Abstract] [Full Text] [Related]
13. New oral anticoagulants in patients with cancer: current state of evidence. Sardar P, Chatterjee S, Herzog E, Pekler G, Mushiyev S, Pastori LJ, Visco F, Aronow WS. Am J Ther; 2015 Jun 01; 22(6):460-8. PubMed ID: 24800791 [Abstract] [Full Text] [Related]
14. Antithrombotic therapy for secondary prevention of unprovoked venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials. Li D, Liu Y, Song Y, Wen A. Ann Med; 2022 Dec 01; 54(1):253-261. PubMed ID: 35023788 [Abstract] [Full Text] [Related]